<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="218265">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00243165</url>
  </required_header>
  <id_info>
    <org_study_id>LifemelCTIL</org_study_id>
    <nct_id>NCT00243165</nct_id>
  </id_info>
  <brief_title>Lifemel Honey to Reduce Leucopenia During Chemotherapy</brief_title>
  <official_title>Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zuf Globus Laboratories Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <brief_summary>
    <textblock>
      This study will include 60 patients with early breast cancer referred to receive adjuvant
      chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide-
      5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel
      honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC
      count will be performed in order to record the influence of Lifemel on myelotoxicity.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of myelotoxicity-every week during chemotherapy.</measure>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifemel honey intake every day</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  breast cancer patient treated with adjuvant chemotherapy

          -  PS = 2 or less

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgeta Fried, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georgeta Fried, MD</last_name>
    <phone>972-4-8543018</phone>
    <email>g_fried@rambam.health.gov.il</email>
  </overall_contact>
  <verification_date>October 2005</verification_date>
  <lastchanged_date>December 4, 2009</lastchanged_date>
  <firstreceived_date>October 20, 2005</firstreceived_date>
  <keyword>breast cancer</keyword>
  <keyword>honey</keyword>
  <keyword>myelosuppression</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Leukopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
